BBI
Brickell Biotech, Inc.
Set alert
52-week range unavailable
- Open
- 2.26
- Prev close
- 2.35
- Mkt cap
- 6.75M
- Vol
- 31.32K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.21
- High
- 2.37
- Forward P/E
- -0.28
- Beta
- 0.08
- Short ratio
- 0.62
- Inst. own
- 13.08%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 11, 2022
- 50-d avg
- 3.10
- 200-d avg
- 8.30
- 1y target
- 17.83
Key statistics
- Market cap
- 6.75M
- Enterprise value
- -7.40M
- Trailing P/E
- 0.00
- Forward P/E
- -0.28
- PEG ratio
- 0.00
- Price / sales
- 1.45
- Price / book
- 0.40
- EPS (TTM)
- -0.42
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.64M
- Revenue growth
- 2757.60%
- Free cash flow
- -19.56M
- Total cash
- 14.48M
- Total debt
- 36.00K
- Return on equity
- -157.29%
- Shares outstanding
- 2.87M
- Short % of float
- 6.73%
- 50-day average
- 3.10
- 200-day average
- 8.30
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 17.83
- Target (high)
- 45.00
Next earnings
Aug 11, 2022
Expected Aug 11, 2022. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 11, 2022 | Jun 1, 2022 | -1.48 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -2.70 | — | — | — |
| Mar 15, 2022 | Dec 1, 2021 | -4.05 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -4.95 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -4.95 | — | — | — |
| May 13, 2021 | Mar 1, 2021 | -5.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 16, 2022 | HC Wainwright & Co. | main | — | Buy |
| May 13, 2022 | Lake Street | down | Buy | Hold |
| Mar 8, 2022 | William Blair | init | — | Outperform |
| Jan 18, 2022 | HC Wainwright & Co. | init | — | Buy |
| Aug 28, 2020 | Lake Street | init | — | Buy |
| Aug 25, 2020 | Oppenheimer | init | — | Outperform |
About Brickell Biotech, Inc.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- brickellbio.com
News
- Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
- Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
- PRESS RELEASE: NACON announces the temporary suspension of trading in its shares on Euronext Paris
- Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
- Boundless Bio Announces Portfolio Prioritization and Runway Extension
- Boundless Bio Announces Pipeline and Leadership Updates
- Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
- Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
- Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
- Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Your note
Sign in to keep a note on BBI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 9, 2019 | 0 |
| BRETON JOSE | Officer | Conversion of Exercise of derivative security | Mar 15, 2021 | 11,919 |
| BROWN ROBERT BUSARD | Chief Executive Officer | Purchase | Mar 14, 2021 | 316,659 |
| CHADHA DEEPAK | Officer | Purchase | May 18, 2021 | 78,167 |
| HARDY REGINALD L | Chairman of the Board | Purchase | Jul 25, 2021 | 780,465 |
| LYONS GARY A | Director | Stock Award(Grant) | Sep 14, 2020 | 24,729 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 2.40% | 68,978 | 162.10K | Jun 29, 2022 |
| Telemetry Investments, L.L.C. | 0.84% | 24,111 | 56.66K | Jun 29, 2022 |
| Palisade Capital Management, L.L.C. | 0.75% | 21,567 | 50.68K | Jun 29, 2022 |
| Millennium Management Llc | 0.39% | 11,127 | 26.15K | Jun 29, 2022 |
| Blackrock Inc. | 0.17% | 4,793 | 11.26K | Jun 29, 2022 |
| UBS Group AG | 0.13% | 3,859 | 9.07K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 11.16% | 320,620 | 753.46K | Jun 29, 2022 |
| Fidelity NASDAQ Composite Index Fund | 3.64% | 104,535 | 245.66K | Jun 29, 2022 |
| Fidelity Total Market Index Fund | 3.26% | 93,690 | 220.17K | Jun 29, 2022 |
| Fidelity Series Total Market Index Fund | 2.39% | 68,718 | 161.49K | Jun 29, 2022 |
| Vanguard Total Stock Market Index Fund | 1.43% | 41,199 | 96.82K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 0.97% | 27,779 | 65.28K | Jun 29, 2022 |